Physician

Adam J Kotkiewicz, D.O.

According to 2025 Medicare claims, Adam Kotkiewicz, D.O. (NPI: 1356491179) practices hematology/oncology in the West Palm Beach-Boca Raton-Delray Beach, FL market, with the plurality of this provider's patient population coming from Palm Beach, FL. This provider's primary affiliated billing organization is CANCER CENTER OF SOUTH FLORIDA PLLC (NPI: 1194990333; TIN: 261666272) and primary practice location at 33410-2853. Kotkiewicz is affiliated with the PBACO Holding, LLC (ACO ID: A1001) and Cleveland Clinic Florida Integrated Health (ACO ID: A3588), participating under the MSSP model.

Kotkiewicz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 316 traditional Medicare patients, billed 883 HCPCS/CPT codes, and received $69,981 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 444 prescription claims across 81 beneficiaries totaling $1,261,695 in drug costs, led by Lenalidomide (Lenalidomide). 2021 DME data shows 12 claims. Open Payments data shows 2 records totaling $475. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,171,033 and ending at $1,261,695. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	325	864	$69,422
2016	370	858	$63,127
2017	372	892	$69,115
2018	389	885	$73,553
2019	403	854	$71,010
2020	370	827	$69,056
2021	340	729	$69,868
2022	124	375	$47,094
2023	223	394	$46,515
2024	316	883	$69,981

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	96	575	$1,171,033
2016	110	694	$1,637,406
2017	135	908	$2,662,390
2018	104	831	$3,409,731
2019	110	677	$2,630,204
2020	113	562	$2,334,595
2021	130	719	$3,010,014
2022	55	189	$336,471
2023	63	201	$402,191
2024	81	444	$1,261,695

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$119
2016	N/R	42	$3,175
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	12	$1,044
2020	N/R	N/R	N/R
2021	N/R	12	$230
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	76	155	$135
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	63	63	$119
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	89	124	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	56	60	$67
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	152	252	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	13	364	$191,180
Brukinsa	Zanubrutinib	13	390	$174,064
Abiraterone Acetate	Abiraterone Acetate	41	1,230	$60,780
Orgovyx	Relugolix	12	360	$30,722
Eliquis	Apixaban	12	420	$8,401

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$475	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam J. Kotkiewicz, D.O.?

Tedicare shows public-source Medicare data for Adam J. Kotkiewicz, D.O. (NPI 1356491179), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam J. Kotkiewicz, D.O. have ACO affiliation data?

Adam J. Kotkiewicz, D.O. is shown with ACO affiliation data for PBACO Holding, LLC (MSSP, ACO ID A1001) and Cleveland Clinic Florida Integrated Health (MSSP, ACO ID A3588).

What billing organization is linked to Adam J. Kotkiewicz, D.O.?

Adam J. Kotkiewicz, D.O. is linked to CANCER CENTER OF SOUTH FLORIDA PLLC (billing NPI 1194990333) in the available physician profile data.

Does Adam J. Kotkiewicz, D.O. have Open Payments data?

Adam J. Kotkiewicz, D.O. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.